Clinical Trials
19 trialsNCT04256317 2026-04-30
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Phase 2/3 Recruiting
NCT04708054 2026-02-19
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
Phase 2/3 Recruiting
NCT02598661 2026-01-05
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Geron Corporation
Phase 2/3 Active not recruiting
NCT03092674 2025-01-16
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT06756152 2025-01-01
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Recruiting
NCT06475820 2024-08-23
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Active not recruiting
NCT03699475 2023-09-29
THRIVE
Bellicum Pharmaceuticals
Phase 2/3 Terminated
NCT02942173 2023-03-16
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Completed
NCT05175508 2022-01-03
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
The First Affiliated Hospital of Soochow University
Phase 2/3 Unknown
NCT00003816 2021-08-13
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
Phase 2/3 Completed
NCT00967343 2021-06-14
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma
Phase 2/3 Terminated
NCT02272478 2020-01-23
AML18
Cardiff University
Phase 2/3 Unknown
NCT00038805 2018-10-31
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2/3 Terminated
NCT00469729 2015-07-10
ExCell
Gamida Cell -Teva Joint Venture Ltd.
Phase 2/3 Completed
NCT00454480 2013-08-26
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00004255 2013-07-10
Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT01809392 2013-03-12
Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
The First Affiliated Hospital of Soochow University
Phase 2/3 Unknown
NCT00003187 2010-02-24
Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma
Virginia Commonwealth University
Phase 2/3 Completed
NCT00300664 2006-10-13
A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.
Royal Marsden NHS Foundation Trust
Phase 2/3 Completed